Jeremy M. Levin - Feb 23, 2023 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)

Role
CEO, Director, 10%+ Owner
Signature
/s/ Danielle Mann for Jeremy Levin by PoA
Stock symbol
OVID
Transactions as of
Feb 23, 2023
Transactions value $
$0
Form type
4
Date filed
2/27/2023, 03:58 PM
Previous filing
Apr 12, 2022
Next filing
Dec 6, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OVID Stock Option (Right to Buy) Award $0 +600K $0.00 600K Feb 23, 2023 Common Stock 600K $2.50 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the Stock Option will vest and become exercisable on February 23, 2024 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date.